Introduction
Malaria remains one of the most prevalent parasitic diseases worldwide, infecting a quarter of a billion people annually and killing almost one million people a year over the last decade (Trigg & Kondrachine, 1998; World Health Organization, 2008) . Protozoan parasites of the genus Plasmodium are the causative agents of malaria and are transmitted to humans by female Anopheles mosquitoes. Of the various species, P. falciparum is responsible for the most lethal and severe form of human malaria (Guerin et al., 2002) .
No effective vaccine is currently available for malaria and infections have mostly been treated through the use of antimalarial drugs such as chloroquine (a quinine derivative), antifolates or artemisinin derivatives. Prophylactic drugs are taken by visitors to malariaendemic regions and must be taken continuously to interfere with the development of the parasite. The drugs in current use belong to a limited collection of chemical structures that act on a small number of partially characterized biochemical targets. The use of closely related compounds has promoted the spread of multidrug-resistant parasites, particularly of P. falciparum (Wongsrichanalai et al., 2002; Arora et al., 2008; Dondorp et al., 2009; Lim et al., 2009; Noedl et al., 2009; Olliaro, 2001; Sutanto et al., 2009) , severely limiting their efficacy. Thus, there is a pressing need for more basic research into the proteins of P. falciparum in order to identify areas of parasite vulnerability and to be able to generate new therapeutics that can uniquely target the malarial parasite.
Aspartate aminotransferases (AspATs; EC 2.6.1.1) typically catalyze the reversible reaction of l-aspartate and -ketoglutarate to oxaloacetate and l-glutamate and have been classified into aminotransferase subgroup I (Mehta et al., 1993) , which has been further subdivided into subgroups Ia and Ib (Okamoto et al., 1996) . Analysis of the homologue from P. falciparum (PfAspAT) placed the enzyme into the Ia subfamily, but the malarial enzyme was the most divergent of the Ia subfamily members (24-31% identity with all other Ia family members). The plasmodial AspATs (P. falciparum, P. vivax and P. berghei) also exhibit the mutation of an invariant glycine 197 that is present in all other AspAT members (Berger et al., 2001; Mehta et al., 1993) .
Although methionine is an essential component to sustain life, many organisms lack the ability to synthesize this amino acid, necessitating its uptake from the environment, in which it is present in scarce quantities. Methionine is required in the biosynthesis of cysteine, phospholipids and polyamines, which are synthesized in large amounts in rapidly growing cells immediately prior to DNA replication. Interference with polyamine biosynthesis or function can completely halt cellular growth. Indeed, compounds that interfere with polyamine biosynthesis have been used successfully against the parasitic protozoa causing African sleeping sickness (Marton & Pegg, 1995) and malaria (Klenke et al., 2003; Das Gupta et al., 2005; Muller et al., 2008) . In order to alleviate the scarcity of methionine, a pathway exists in mammals and bacteria that regenerates methionine from methylthioadenosine (Heilbronn et al., 1999) and it has been postulated that interference with other enzymes that are involved in the regeneration of methionine could lead to cell death in P. falciparum (Sufrin et al., 1995) .
Berger and coworkers demonstrated that PfAspAT (PlasmoDB PFB0200c) is able to efficiently use aspartate and tyrosine as substrates to catalyze the transamination of -ketomethiobutyrate (KTMB) to regenerate methionine. However, other researchers have identified branched-chain aminotransferases as being responsible for the amino acid-KMTB aminotransfer reaction in Homo sapiens (Davoodi et al., 1998) . Thus, humans and the malarial parasite potentially use different enzymes and different substrates in the regeneration of methionine. While doubts have recently been cast upon methionine regeneration in P. falciparum (Ting et al., 2005) , suggesting that the transamination activity of PfAspAT may be involved in other pathways, the essential nature of PfAspAT has been demonstrated by the finding that the aminooxy compound canaline can inhibit its activity in parasite homogenates and has antimalarial effects in vitro (Berger, 2000; Berger et al., 1998; Heilbronn et al., 1999) .
Thus, AspAT represents a novel and potentially highly selective target for therapeutics against P. falciparum. Elucidation of the structure of PfAspAT will aid in the design of drugs to selectively inhibit the plasmodial AspAT and will provide further information about the role and function of PfAspAT within the malarial parasite. In this communication, we report the purification, crystallization and preliminary X-ray diffraction of P. falciparum AspAT.
Methods

Cloning and expression of pASK-IBA3-PfAspAT
The open reading frame encoding PfAspAT was amplified by PCR from P. falciparum 3D7 genomic DNA using sequence-specific antisense (5 0 -GCGCGCGGTCTCAGCGCTTTAATGATGATGAT-GATGATGGCCCTGAAAATAAAGATTCTCTATTTGACTTAG-CGAAAGACAAATTTTGTCGG-3 0 ) and sense (5 0 -GCGCGC-GGTCTCCAATGGATAAGTTATTAAGCAGCTTAG-3 0 ) oligonucleotides. The PCR for the construct was performed using Pfu polymerase (Promega, USA) and the following PCR program: denaturation for 5 min at 368 K followed by 30 cycles of 50 s at 368 K, 90 s at 315 K and 2 min at 345 K. The generated PCR product was digested with BsaI and cloned into the Escherichia coli expression plasmid pASK-IBA3 previously digested with the same enzyme, resulting in the expression construct PfAspAT-IBA3. The antisense oligonucleotide encodes a TEV protease site (ENLYFQ) immediately following the native C-terminus followed by a single Gly and a 6ÂHis tag that allows purification of the recombinant fusion protein using Ni-NTA agarose (Qiagen). The final construct consists of 418 amino acids and has a molecular weight of 48 680 Da. The nucleotide sequence was verified by automated nucleotide sequencing (MWG, Germany). Nucleotide and amino-acid analyses were performed with the Gene Runner software (Hastings Software Inc.). Protein expression was performed using E. coli strain BL21 (DE3) and was induced with 200 ng ml À1 anhydrotetracycline at an OD 600 of 0.5 and a temperature of 310 K. Cell cultures were harvested by centrifugation 4 h post-induction, resuspended in 50 mM sodium phosphate buffer pH 7.5 containing 300 mM NaCl and 10 mM imidazole (buffer L) and frozen at 253 K prior to purification. The final yield of purified protein was approximately 1.3 mg per litre of culture.
Purification of PfAspAT
Following cell lysis in buffer L and clarification by centrifugation, the soluble fraction of the lysate was applied onto an Ni-NTA column previously incubated in buffer A (100 mM Tris-HCl pH 8.0, 150 mM NaCl) with an additional 20 mM imidazole (buffer W). The bound sample was washed extensively in buffer W and eluted in buffer A with an additional 300 mM imidazole (buffer E). Following overnight dialysis against buffer A, the sample was applied onto a MonoQ HR 5/5 anion-exchange column (GE Healthcare) previously equilibrated in buffer A. The protein was eluted using a linear gradient from 0.15 to 1.0 M NaCl and eluted as a single peak between 0.35 and 0.38 M NaCl. The peak fractions were pooled, concentrated to 1 ml and injected onto a Superdex-75 16/60 size-exclusion column previously equilibrated in buffer A. PfAspAT eluted as a highly homogeneous single peak as determined using static light scattering (Nettleship et al., 2008) . The purity of the sample was also assessed after ion-exchange and size-exclusion chromatography on SDS-PAGE (Laemmli, 1970;  Fig. 1 ) and concentrations were determined using an absorption coefficient calculated from the primary sequence [" o (280 nm) = 0.852 mg À1 ml]. In order to improve protein stability and homogeneity, the cofactor pyridoxal 5 0 -phosphate (PLP) was added to the purified protein at a concentration of 2.5 mM to ensure full cofactor binding. The sample was then concentrated to 6 mg ml À1 in buffer A prior to initial crystallization screening. No removal of the affinity tag was performed. 
Results and discussion
Crystallization of PfAspAT
Once purified, the protein was screened for crystallization using the EMBL Hamburg high-throughput robotic crystallization facility (Mueller-Dieckmann, 2006 ) and the presence of crystals was confirmed using a protein-specific fluorescent dye (Groves et al., 2007) . The preliminary crystallization conditions were (i) 1.4 M trisodium citrate, 0.1 M HEPES pH 7.5 and (ii) 2.0 M ammonium sulfate, 0.1 M Tris-HCl pH 8.5.
While the initial crystallization conditions resulted in highly disordered clusters of crystals, subsequent grid screening (Weber, 1990; McPherson, 1990 ) based upon the above conditions resulted in a single crystal (with a minor satellite) that was suitable for diffraction data collection (Fig. 2) . The optimized crystal used in diffraction data collection was grown from 1.5 ml protein solution at a concentration of 5.4 mg ml À1 in buffer A mixed with an equal volume of reservoir solution (2.0 M ammonium sulfate, 0.1 M bis-tris-HCl pH 7.0) at 293 K.
Diffraction experiment and data processing
While only a single diffraction-quality protein crystal was obtained, cryoprotection conditions could be established using the disordered plate clusters, which exhibited reasonably strong disordered diffraction to better than 5 Å resolution. Crystals were transferred into a stabilizing solution [2 M ammonium sulfate, 25%(w/v) glycerol, 0.1 M bis-tris-HCl pH 7.0] based upon an initial estimate of cryoconditions from Garman & Mitchell (1996) and were subsequently flash-cooled in a nitrogen-gas stream at 100 K. Initial frames were collected on beamline ID23-2 at ESRF to allow crystal characterization and spacegroup assignment using the software MOSFLM (Leslie, 2006) and BEST (Bourenkov & Popov, 2006; Popov & Bourenkov, 2003) . Data were integrated with XDS (Kabsch, 1988) and scaled using SCALA (Evans, 2006) . The crystals of PfAspAT belonged to space group H32, with unit-cell parameters a = b = 101.0, c = 240.7 Å . An examination of the expected solvent content strongly suggested the asymmetric unit to consist of one molecule, with a Matthews coefficient (V M ) of 2.49 Å 3 Da À1 and a solvent content of 50.8% (Kantardjieff & Rupp, 2003; Matthews, 1968) . In order to make efficient use of the small beam size and reduce the effect of radiation damage, four independent data sets were collected from different parts of the crystal (Fig. 2 ) to 2.8 Å resolution as a total of 110 nonoverlapping 1 oscillation images. A total of 28 1 oscillations were collected for the first three data sets, with the fourth data set being composed of 26 1 oscillations. A summary of the data-collection parameters and integration statistics of all four data sets is given in Table 1 .
Molecular replacement using BALBES (Long et al., 2008) , with PDB entry 2q7w (Liu et al., 2007; Berman et al., 2000) as a search model, resulted in an initial model with R and R free factors of 0.344 and 0.416, respectively. The search model possesses an overall sequence identity of 31%. Model building using Coot (Emsley & Cowtan, 2004) is currently under way and the structure and analysis will be described in a subsequent manuscript. Crystallization of and data collection from a PfAspAT crystal. Optimization of the crystallization conditions resulted in a single PfAspAT crystal with a maximum dimension of $80 mm (a). Multiple (four) data sets were collected from this crystal using a beam size of 20 Â 20 mm on beamline ID23-2 at the ESRF (b), with care being taken to avoid the satellite crystals (highlighted with an arrow). Diffraction maxima were recorded to a maximum resolution of 2.8 Å . ID23-2, ESRF for their support during data collection. This work was supported by a grant from Deutsche Forschungsgemeinschaft (WR 124/2).
